Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 37: 1356-1364, 1991;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silva, D. P.
Right arrow Articles by Ladenson, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silva, D. P., Jr
Right arrow Articles by Ladenson, J. H.

Clinical Chemistry, Vol 37, 1356-1364, Copyright © 1991 by American Association for Clinical Chemistry

Development and application of monoclonal antibodies to human cardiac myoglobin in a rapid fluorescence immunoassay

DP Silva Jr, Y Landt, SE Porter and JH Ladenson
Washington University School of Medicine, Department of Pathology, St. Louis, MO 63110.

Myoglobin (Mb) is considered a useful marker for early detection of myocardial infarction and for monitoring cardiac reperfusion after thrombolytic therapy. We developed eight monoclonal antibodies to human cardiac Mb, characterized their epitopic reactivity, and determined which combinations of the antibodies are useful in two-site immunoassays. We configured two of the monoclonal antibodies in a one- step, two-site particle concentration fluorescence immunoassay (PCFIA) for measurement of Mb. The PCFIA has rapid kinetics of reaction, being complete in 15 min, and has a linear analytical range of 20-675 micrograms/L for human Mb. Although the PCFIA has a high-dose "hook" effect, this is of no analytical importance at concentrations of Mb less than or equal to 148,000 micrograms/L. The assay is not subject to interference from icterus (bilirubin less than or equal to 360 mg/L), has no cross-reaction with hemoglobin (less than or equal to 42 g/L), and may be performed with either plasma or serum in approximately 1 h. The intra- and interassay imprecisions (CV) of the method are less than 10% for concentrations of Mb within the normal range and less than 4% at higher concentrations. A comparison of the PCFIA with a commercial radioimmunoassay showed that results of the two assays correlate well (PCFIA = 0.88 x RIA + 18, r = 0.990, n = 171).


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
S. B. Rosalki, R. Roberts, H. A. Katus, E. Giannitsis, J. H. Ladenson, and F. S. Apple
Cardiac Biomarkers for Detection of Myocardial Infarction: Perspectives from Past to Present
Clin. Chem., November 1, 2004; 50(11): 2205 - 2213.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
B. Jurlander, P. Clemmensen, G. S. Wagner, and P. Grande
Very early diagnosis and risk stratification of patients admitted with suspected acute myocardial infarction by the combined evaluation of a single serum value of cardiac troponin-T, myoglobin, and creatine kinase MBmass
Eur. Heart J., March 1, 2000; 21(5): 382 - 389.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
M. J. Tanasijevic, C. P. Cannon, E. M. Antman, D. R. Wybenga, G. A. Fischer, C. Grudzien, C. M. Gibson, J. W. Winkelman, E. Braunwald, and for the TIMI 10B Investigators
Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: Results from the thrombolysis in myocardial infarction study (TIMI) 10B
J. Am. Coll. Cardiol., September 1, 1999; 34(3): 739 - 747.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Association for Clinical Chemistry.